KFDA to assess safety of clevudine

Published: 2009-05-06 06:59:00

Updated: 2009-05-06 06:59:00

Now all eyes are on the Korea Food and Drug Administration Committee’s decision on the safety problems of Levovir (clevudine), an investigatory hepatitis B treatment.

The KFDA will be given advice from the Central Pharmaceutical Affairs Review Committee for the drug safety on May 7.

It's st...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK